PSB-KD107

PSB-KD107

Identifiers
IUPAC name 9-[2-(1H-indol-3-yl)ethyl]-1,3-dimethyl-7,8-dihydro-6H-purino[7,8-a]pyrimidine-2,4-dione
CAS Number	955121-65-0
PubChem CID	44437220
Chemical and physical data
Formula	C20H22N6O2
Molar mass	378.436 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C2=C(C(=O)N(C1=O)C)N3CCCN(C3=N2)CCC4=CNC5=CC=CC=C54
InChI InChI=1S/C20H22N6O2/c1-23-17-16(18(27)24(2)20(23)28)26-10-5-9-25(19(26)22-17)11-8-13-12-21-15-7-4-3-6-14(13)15/h3-4,6-7,12,21H,5,8-11H2,1-2H3 Key:PUJKERUFRDZALE-UHFFFAOYSA-N

PSB-KD107 is an experimental drug that acts as a potent and selective agonist for the cannabinoid-like NAGly receptor, also known as GPR18. It has antiinflammatory effects, and has been studied in an animal model of Duchenne muscular dystrophy. ^{[1] [2]}

References

1. Schoeder CT, Mahardhika AB, Drabczyńska A, Kieć-Kononowicz K, Müller CE (October 2020). "Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18". ACS Medicinal Chemistry Letters. 11 (10): 2024–2031. doi:10.1021/acsmedchemlett.0c00208. PMC   7549263 . PMID   33062188.
2. Dort J, Orfi Z, Fiscaletti M, Campeau PM, Dumont NA (2023). "Gpr18 agonist dampens inflammation, enhances myogenesis, and restores muscle function in models of Duchenne muscular dystrophy". Frontiers in Cell and Developmental Biology. 11: 1187253. doi: 10.3389/fcell.2023.1187253 . PMC   10461444 . PMID   37645248.